Multivariable analysis of factors influencing OS, EFS, and EFS censoring patients at the time of SCT
| Variable . | P . | Hazard ratio . | 95% CI . |
|---|---|---|---|
| OS of all patients | |||
| High (≥0.44) NPM1 VAF | <.0001 | 4.043 | 2.037-8.024 |
| DNMT3A mutation | .017 | 2.381 | 1.165-4.869 |
| EFS of all patients | |||
| High (≥0.44) NPM1 VAF | <.0001 | 3.777 | 1.946-7.333 |
| DNMT3A mutation | .023 | 2.088 | 1.107-3.939 |
| SCT in CR1 | .003 | 0.365 | 0.188-0.711 |
| EFS of all patients censored at time of SCT | |||
| Age (continuous, per year) | .01 | 1.044 | 1.010-1.078 |
| Combined FLT3-ITD and DNMT3A mutation | .02 | 2.71 | 1.171-6.273 |
| Variable . | P . | Hazard ratio . | 95% CI . |
|---|---|---|---|
| OS of all patients | |||
| High (≥0.44) NPM1 VAF | <.0001 | 4.043 | 2.037-8.024 |
| DNMT3A mutation | .017 | 2.381 | 1.165-4.869 |
| EFS of all patients | |||
| High (≥0.44) NPM1 VAF | <.0001 | 3.777 | 1.946-7.333 |
| DNMT3A mutation | .023 | 2.088 | 1.107-3.939 |
| SCT in CR1 | .003 | 0.365 | 0.188-0.711 |
| EFS of all patients censored at time of SCT | |||
| Age (continuous, per year) | .01 | 1.044 | 1.010-1.078 |
| Combined FLT3-ITD and DNMT3A mutation | .02 | 2.71 | 1.171-6.273 |
CI, confidence interval.